<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04002154</url>
  </required_header>
  <id_info>
    <org_study_id>PHPC-201501</org_study_id>
    <nct_id>NCT04002154</nct_id>
  </id_info>
  <brief_title>Clinical Trial to Explore the Papilocare Gel Efficacy to Repair the Cervico-vaginal Mucosa With Lesions Caused by HPV</brief_title>
  <acronym>PALOMA</acronym>
  <official_title>Ensayo clínico, Aleatorizado, Abierto, de Grupos Paralelos y Con Grupo Control, Para Explorar la Eficacia Del Gel PAPILOCARE en la reparación de la Mucosa cérvico-vaginal Con Lesiones Causadas Por VPH (Ensayo Clínico PALOMA)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Procare Health Iberia S.L.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Adknoma Health Research</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Procare Health Iberia S.L.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Phase II, exploratory, randomized, open, controlled and parallel groups clinical trial to
      evaluate the effectiveness of exploratory gel Papilocare in the repair of the cervico-vaginal
      mucosa with lesions caused by HPV. All the patients included in the study will be Randomized
      (1:1:1) to Arm A (Papilocare schedule A), Arm B (Papilocare schedule B) and Arm C (usual
      clinical practice -without treatment-). Selection period of 1 month, followed by
      randomization and 6 months of treatment followed by a period of another 6 months without
      treatment. Patients will visit the site into a total of 5 visits throughout the study.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 19, 2015</start_date>
  <completion_date type="Actual">February 28, 2019</completion_date>
  <primary_completion_date type="Actual">July 31, 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Repairment of the cervico-vaginal mucosa in positive HPV women measured by normal cytology with concordant colposcopy image</measure>
    <time_frame>6 months</time_frame>
    <description>Evaluate the repairment of the cervico-vaginal mucosa in positive HPV women with a cytological result of squamous atypia of undetermined significance (ASC-US) or low-grade squamous lesion (LSIL) or glandular atypia of undetermined significance (AG-US), with concordant colposcopic image, 6 months after the start of treatment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Repairment of the cervico-vaginal mucosa in positive HPV women measured by normal cytology with concordant colposcopy image</measure>
    <time_frame>3 and 12 months</time_frame>
    <description>Evaluate the repairment of the cervico-vaginal mucosa in positive HPV women with a cytological result of squamous atypia of undetermined significance (ASC-US) or low-grade squamous lesion (LSIL) or glandular atypia of undetermined significance (AG-US), with concordant colposcopic image at 3 and 12 months after the start of treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reeptielization of the cervico-vaginal mucosa measured by a likert scale.</measure>
    <time_frame>3,6 and 12 months</time_frame>
    <description>Evaluate the reeptielization of the cervico-vaginal mucosa at 3, 6 and 12 months after the start of treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vaginal health status measured by Bachmann Index.</measure>
    <time_frame>3,6 and 12 months</time_frame>
    <description>Evaluate vaginal health status at 3, 6 and 12 months from the start of treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Satisfaction of papilocare gel use measured by likert scale.</measure>
    <time_frame>3 and 6 months</time_frame>
    <description>Evaluate the satisfaction of papilocare gel use by the patients at 3 and 6 months after the start of treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Therapeutic compliance measured by a likert scale.</measure>
    <time_frame>3 and 6 months</time_frame>
    <description>Evaluate the therapeutic compliance at 3 and 6 months after the start of treatment.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">134</enrollment>
  <condition>Human Papilloma Virus Infection</condition>
  <condition>Human Papilloma Virus</condition>
  <condition>Cervix Lesion</condition>
  <arm_group>
    <arm_group_label>A - papilocare alternative days</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Arm A: scheme A (21 days / 1 cannula per day + 7 days rest) x 1 month + alternate days up to 6 months (except for menstruation days)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B - papilocare semiintensive</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Arm B: scheme B (21 days / 1 cannula per day + 7 days rest) x 3 months + alternate days up to 6 months (except menstruation days)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>C - standard of care</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Arm C: usual clinical practice: no treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Papilocare vaginal gel</intervention_name>
    <description>Papilocare is a gel vaginally administered by a single-dose cannula. Vaginal gel formulation is effective as a local treatment with controlled systemic absorption and rapid and efficient distribution</description>
    <arm_group_label>A - papilocare alternative days</arm_group_label>
    <arm_group_label>B - papilocare semiintensive</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Woman between the ages of 30 and 65 (both included).

          2. Able to read and understand the Patient Information Sheet and the Informed Consent
             form.

          3. Accept participation in the study and sign the Informed Consent form.

          4. Cytological result of ASC-US or LSIL or AG-US, with matching colposcopic image,
             maximum 3 months before the screening visit.

          5. Positive HPV by PCR performed at the screening visit (or positive available at most 3
             months prior to the baseline visit).

          6. Is capable, at the discretion of the investigator, of complying with the requirements
             of the study protocol and without impediments to follow the instructions and
             evaluations throughout it.

        Exclusion Criteria:

          1. Clinically relevant immune system alterations, or any other autoimmune disease or in
             treatment with immunosuppressants.

          2. Non-diagnosed abnormal genital hemorrhage (during the 6 months prior to the screening
             visit).

          3. To had been vaccinated against HPV.

          4. Other symptomatic vulvovaginal infections.

          5. Surgical cervical excision in the last year or total hysterectomy.

          6. Previous history of gynecological cancer.

          7. Participation in any other clinical trial at present or in the 4 weeks prior to the
             inclusion of the study.

          8. Any planned surgery that prevents the correct compliance with the protocol.

          9. Use of vaginal contraceptives or other vaginal hormonal treatments.

         10. Contraindications for Papilocare gel use or known allergies to any of its components.

         11. Women of childbearing age who do not use effective contraceptive methods, pregnant
             women, with suspicion of pregnancy or woman who are breastfeeding.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Javier Cortés Bordoy, ÇMD</last_name>
    <role>Study Chair</role>
    <affiliation>SEGO (sociedad española de ginecología y obstetricia)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital General Universitario de Alicante</name>
      <address>
        <city>Alicante</city>
        <zip>03010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clínica Diatros - TEKNON</name>
      <address>
        <city>Barcelona</city>
        <zip>08017</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Women´s Health Institute</name>
      <address>
        <city>Barcelona</city>
        <zip>08017</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de la Santa Creu i Sant Pau</name>
      <address>
        <city>Barcelona</city>
        <zip>08041</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gabinete Médico Velázquez</name>
      <address>
        <city>Madrid</city>
        <zip>28001</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Infanta Leonor</name>
      <address>
        <city>Madrid</city>
        <zip>28031</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clínico San Carlos</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto Palacios de Salud y Medicina de la Mujer</name>
      <address>
        <city>Madrid</city>
        <zip>41720</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Quirón Málaga</name>
      <address>
        <city>Málaga</city>
        <zip>29004</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>June 2019</verification_date>
  <study_first_submitted>June 21, 2019</study_first_submitted>
  <study_first_submitted_qc>June 27, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 28, 2019</study_first_posted>
  <last_update_submitted>June 27, 2019</last_update_submitted>
  <last_update_submitted_qc>June 27, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">June 28, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HPV</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Papillomavirus Infections</mesh_term>
    <mesh_term>Papilloma</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>It must be discussed with investigators team</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

